CHIVAX-GD Trademark

Trademark Overview

On Friday, July 12, 2019, a trademark application was filed for CHIVAX-GD with the United States Patent and Trademark Office. The USPTO has given the CHIVAX-GD trademark a serial number of 88512576. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, August 23, 2021. This trademark is owned by Virion Therapeutics, LLC. The CHIVAX-GD trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of vaccines and medicines, namely, the development of vaccine platform technologies; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, research, development, engineering and testing services focused on vaccine platform technologies; scientific research in the field of vacciness, namely, research and development of cell preparations, cellular vaccines, and therapeutics for the treatment of cancer and infectious diseases; research and development of technology in the field of immunotherapy platforms for manufacturing t-cell based therapeutics for cancer and infectious diseases
chivax-gd

General Information

Serial Number88512576
Word MarkCHIVAX-GD
Filing DateFriday, July 12, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, August 23, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 28, 2020

Trademark Statements

Goods and ServicesResearch and development of vaccines and medicines, namely, the development of vaccine platform technologies; research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, research, development, engineering and testing services focused on vaccine platform technologies; scientific research in the field of vacciness, namely, research and development of cell preparations, cellular vaccines, and therapeutics for the treatment of cancer and infectious diseases; research and development of technology in the field of immunotherapy platforms for manufacturing t-cell based therapeutics for cancer and infectious diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 18, 2019
Primary Code042
First Use Anywhere DateMonday, February 5, 2018
First Use In Commerce DateMonday, February 5, 2018

Trademark Owner History

Party NameVirion Therapeutics, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNewark, DE 19711
Party NameVirion Therapeutics, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNewark, DE 19711

Trademark Events

Event DateEvent Description
Monday, February 7, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, February 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, February 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, February 7, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 23, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, August 23, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, February 8, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 8, 2021NON-FINAL ACTION E-MAILED
Monday, February 8, 2021SU - NON-FINAL ACTION - WRITTEN
Thursday, January 7, 2021STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 17, 2020USE AMENDMENT FILED
Thursday, January 7, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 17, 2020TEAS STATEMENT OF USE RECEIVED
Tuesday, June 23, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 28, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 24, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 24, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 20, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, March 17, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, March 17, 2020FINAL REFUSAL E-MAILED
Tuesday, March 17, 2020FINAL REFUSAL WRITTEN
Monday, February 24, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 24, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, February 22, 2020ASSIGNED TO LIE
Saturday, February 15, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, February 15, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, February 15, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, February 15, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, February 15, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, February 15, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, September 27, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION WRITTEN
Friday, September 27, 2019ASSIGNED TO EXAMINER
Thursday, July 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 16, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

chivax development research namely vaccines field cell diseases cancer infectious therapeutics